SecBot SecBot
PRESS-RELEASE ·Filed Apr 27, 2026

ERAS

Erasca, Inc.
BULLISH
Impact 8/10
Horizonimmediate Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Conference call today at 4:30 PM ET may provide additional details. Monitor for analyst upgrades and potential partnership interest. Data readouts in H1 2027 are next catalyst.

DirectionBullish
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$9.90
T+0 close · Apr 27, 2026 · via day close
Latest settled
+95.35%
T+60 · $19.34
Vs SPY
+91.36%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 28 $9.90entry
  2. T+1 · 7mo ago −6.41%α −6.40% · $9.27
  3. T+5 · 7mo ago +2.42%α +0.73% · $10.14
  4. T+20 · 6mo ago +16.16%α +10.69% · $11.50
  5. T+60 · 4mo ago +95.35%α +91.36% · $19.34
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Erasca reported highly positive preliminary Phase 1 data for pan-RAS inhibitor ERAS-0015, showing 62% uORR in 2L+ KRAS G12X NSCLC (vs 38% for comparator RMC-6236) and 40% uORR in 2L PDAC (vs 29% comparator), with favorable safety. This is a major catalyst for the stock, potentially positioning ERAS-0015 as best-in-class.

Key Facts

  • 62% uORR in 2L+ KRAS G12X NSCLC at PAD 16-32 mg QD vs 38% comparator
  • 75% uORR in post-ICI/platinum 2/3L NSCLC at PAD vs 38% comparator
  • 40% uORR in 2L KRAS G12X PDAC at PAD vs 29% comparator
  • No DLTs, low-grade AEs, no discontinuations due to TRAEs
  • RDE selected as 24-32 mg QD; monotherapy expansion and combo cohorts initiated
  • Anticipated data disclosure narrowed to H1 2027

Financial Impact

Significant valuation increase expected; ERAS-0015 could address large NSCLC and PDAC markets if approved

Risk Factors

  • Data are preliminary and based on small sample sizes; unconfirmed responses
  • Cross-trial comparison limitations with RMC-6236
  • Regulatory and clinical development risks; need to confirm durability

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3281996

Track record

26 reports on ERAS

Performance horizon

3 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +95.35% at T+60 after the Apr 27, 2026 report. 6 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry $15.21 Now $15.11 −0.66% settles Feb 12
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.31 Now $15.11 −1.31% settles Feb 12
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.35 Now $15.11 −1.56% settles Feb 12
  4. Nov 12, 20264d ago Press Release Neutral 4/10 Entry $15.66 Now $15.11 −3.51% settles Feb 11
  5. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $14.64 Now $15.11 +3.21% settles Feb 1
  6. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $13.39 Now $15.11 +12.85% settles Jan 13
  7. Aug 24, 202612w ago 8-K Bullish 5/10 Entry $17.60 Now $15.11 −14.15% settles Nov 17
  8. Aug 17, 202613w ago 144 Neutral 3/10 Entry $18.28 to $15.61 Now $15.11 −17.34% ▼ −14.61% −11.84% vs SPY
  9. Aug 13, 202613w ago Institutional Cluster Bullish 6/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
  10. Aug 12, 202613w ago 3 Neutral 2/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 9h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 27, 2026